Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sunmin Lee

Showing results (211-220 of 228) with videos related to

Pageof 23
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2011
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cellsJohanny Tonos De Leon, Aki Iwai, Clementine Feau, et al.
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Neuro-Oncology|October 31, 2019
Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomasVictor Ruiz-Rodado, Tathiane M Malta, Tomohiro Seki, et al.
Clinical Genitourinary Cancer|June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial CarcinomaAndrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid TumorsAnish Thomas, Christophe E Redon, Linda Sciuto, et al.
Molecular Cancer Therapeutics|June 24, 2018
Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal AdenocarcinomaPaul L Feingold, Deborah R Surman, Kate Brown, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.
BJU International|September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
Pageof 23

Showing results (211-220 of 228) with videos related to

Sort By:
Pageof 23
Proceedings of the National Academy of Sciences of the United States of America|July 7, 2011
Targeting the regulation of androgen receptor signaling by the heat shock protein 90 cochaperone FKBP52 in prostate cancer cellsJohanny Tonos De Leon, Aki Iwai, Clementine Feau, et al.
Leukemia Research|September 26, 2021
Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemiaHetty E Carraway, Yazeed Sawalha, Ivana Gojo, et al.
Neuro-Oncology|October 31, 2019
Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomasVictor Ruiz-Rodado, Tathiane M Malta, Tomohiro Seki, et al.
Clinical Genitourinary Cancer|June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial CarcinomaAndrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid TumorsAnish Thomas, Christophe E Redon, Linda Sciuto, et al.
Molecular Cancer Therapeutics|June 24, 2018
Induction of Thioredoxin-Interacting Protein by a Histone Deacetylase Inhibitor, Entinostat, Is Associated with DNA Damage and Apoptosis in Esophageal AdenocarcinomaPaul L Feingold, Deborah R Surman, Kate Brown, et al.
BJU International|January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
Journal for Immunotherapy of Cancer|December 6, 2018
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, David VanderWeele, Ravi A Madan, et al.
BJU International|September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancerRavi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
Journal for Immunotherapy of Cancer|March 25, 2026
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancerChennan Li, Ravi A Madan, Min-Jung Lee, et al.
Pageof 23